- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
The cannabis producer confirmed a new partnership with Sandoz for the potential development of new medical cannabis products.
In another step of major industries moving into the cannabis space, generic pharmaceutical company Sandoz will now collaborate with Canadian licensed producer (LP) Tilray (NASDAQ:TLRY) for medical cannabis products.
On Tuesday (December 18), the LP confirmed a new “global framework agreement” with the life science company.
“Sandoz AG will be a valuable partner as we work together to improve access to the highest quality medical cannabis products in countries all over the world,” said Brendan Kennedy, CEO of Tilray.
Tilray already formed a relationship with the pharmaceutical world in March, when the cannabis venture announced an exclusive collaboration with Sandoz Canada, an affiliate of Sandoz International.
This is the next step between Tilray and the Canadian division of Sandoz, which itself is part of the Novartis (NYSE:NVS) group.
As part of the collaboration, the two companies could work together to commercialize non-smokable medical cannabis products. Sandoz may also participate in co-branding these products.
Through the deal, Sandoz can obtain medical cannabis products or access to Tilray’s license rights and may participate in the development of new products.
“Both companies may also partner to leverage best-in-class knowledge to educate pharmacists and physicians about medical cannabis products,” Tilray added.
Shares of Tilray shot up 16.1 percent in Tuesday’s trading session, while during after-hours trading the company was up just over 1 percent. Tilray closed at US$76.50.
The pharmaceutical industry has been at the forefront of markets predicted to be interested in partnerships in the cannabis space due to the medical aspect.
Dena Jalbert, founder and CEO of Align Business Advisory Services, previously told the Investing News Network that she expects more deals where a larger player steps into cannabis to be based on intellectual property rather than a full buyout.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.